Abstract
The clinical trial of BNT162b2 at age 12-15 years reported 100% effectiveness in preventing COVID-19 after 7 days from dose-2, which is administrated at day 21. We reanalyzed the data and found 100% effectiveness also after 14-20 days from dose-1 administration. This could relate to studies showing increased dose-1 effectiveness at younger ages. Our findings support the possibility of vaccinating younger ages with the United Kingdom regimen, which delays dose-2 to day 84 to allow more dose-1 vaccinations.
Original language | English |
---|---|
DOIs | |
State | Published - 2021 |